Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00077337 · ClinicalTrials.gov registry record · Phase 2

FR901228 in Treating Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Cancer

A Phase 2 study, sponsored by SWOG Cancer Research Network.

Completed
Registry status
Phase 2
Development phase

NCT00077337: Completed Phase 2 study, sponsored by SWOG Cancer Research Network.

NCT00077337 is a Phase 2 study that has completed, run by SWOG Cancer Research Network. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00077337, a Phase 2 study, has completed, sponsored by SWOG Cancer Research Network.

COMPLETED
Registry status
Phase 2
Development phase

Study Summary

RATIONALE: Drugs used in chemotherapy, such as FR901228, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well FR901228 works in treating patients with unresectable locally advanced or metastatic colorectal cancer.

Interventions

  • DRUG romidepsin

Trial Details

FieldValue
Start Date 2004-04
Est. Completion 2006-04
Phase Phase 2
SWOG Cancer Research Network

270 total trials

What the finished NCT00077337 record still lists

NCT00077337 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 1 intervention - of which romidepsin is the first listed.

NCT00077337 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00077337 about?

NCT00077337 is a clinical study titled "FR901228 in Treating Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Cancer". RATIONALE: Drugs used in chemotherapy, such as FR901228, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well FR901228 works in treating patients with unresectable locally advanced or metastatic colorectal cancer.

What is the current status of trial NCT00077337?

This trial is currently completed. It is a Phase 2 study. The study started on 2004-04. Estimated completion is 2006-04.

What interventions are being tested in trial NCT00077337?

The interventions under investigation include: romidepsin (DRUG).

Who is sponsoring clinical trial NCT00077337?

This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00077337, the US trial registry maintained by the National Library of Medicine. NCT00077337 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.